Equity Profile

BLCO

Bausch + Lomb Corporation

Health CareHealth Care Supplies$6.1B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Bausch + Lomb Corporation (BLCO) is a healthcare company specializing in eye health products, including contact lenses and surgical devices. With a market cap of $6 billion, it plays a crucial role in the growing health care supplies sector, particularly as demand for vision correction and eye care continues to rise.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet consumer demand, which is vital for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BLCO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-75.76%

Avg Stock Reaction

-2.86%

Last Quarter Recap

In Q1-2026, Bausch + Lomb reported an EPS of $0.05, missing expectations by 10.71%. The stock reacted negatively, dropping 2.42% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bausch + Lomb are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors will be watching closely for any signs of improvement.

Bull Case

If the company can show a significant rebound in EPS and revenue growth, it may signal a turnaround, boosting investor confidence and stock performance.

Bear Case

Conversely, if the company continues to miss earnings expectations, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bausch + Lomb's EPS exceed $0.05 this quarter?

Given their recent history of missing estimates, a positive EPS could signal a recovery and boost investor confidence.

What specific revenue growth can we expect in the eye health segment?

Investors will be looking for clear indications of growth in this key area to assess the company's future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Bausch + Lomb's performance, given the recent focus on eye health products.

Supporting Evidence

The options market is pricing an 8.12% move, indicating expectations of volatility that may not align with recent performance trends.

Bausch + Lomb has historically shown the ability to rebound from prior misses, suggesting potential for positive surprises.

Key Risk

If the company reports an EPS above $0.05, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it follows a pattern of missed earnings, and investors are eager for signs of improvement.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.05 would reinforce the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±8.12%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move of over 8%, indicating that traders expect volatility around the earnings report.

Options are pricing ±8.1% while BLCO has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.7%

Calls (4K)P/C Ratio: 0.02Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch + Lomb beats expectations, history suggests the stock could see a modest uptick, confirming a positive shift in performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average drop of around 4.57% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the eye health segment.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for contact lenses and surgical products.
4Guidance on revenue expectations for the upcoming quarters.
5Any strategic partnerships or collaborations announced.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet consumer demand, which is vital for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BLCO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-75.76%

Avg Stock Reaction

-2.86%

Last Quarter Recap

In Q1-2026, Bausch + Lomb reported an EPS of $0.05, missing expectations by 10.71%. The stock reacted negatively, dropping 2.42% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bausch + Lomb are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors will be watching closely for any signs of improvement.

Bull Case

If the company can show a significant rebound in EPS and revenue growth, it may signal a turnaround, boosting investor confidence and stock performance.

Bear Case

Conversely, if the company continues to miss earnings expectations, it could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bausch + Lomb's EPS exceed $0.05 this quarter?

Given their recent history of missing estimates, a positive EPS could signal a recovery and boost investor confidence.

What specific revenue growth can we expect in the eye health segment?

Investors will be looking for clear indications of growth in this key area to assess the company's future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Bausch + Lomb's performance, given the recent focus on eye health products.

Supporting Evidence

The options market is pricing an 8.12% move, indicating expectations of volatility that may not align with recent performance trends.

Bausch + Lomb has historically shown the ability to rebound from prior misses, suggesting potential for positive surprises.

Key Risk

If the company reports an EPS above $0.05, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it follows a pattern of missed earnings, and investors are eager for signs of improvement.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.05 would reinforce the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±8.12%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move of over 8%, indicating that traders expect volatility around the earnings report.

Options are pricing ±8.1% while BLCO has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.7%

Calls (4K)P/C Ratio: 0.02Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch + Lomb beats expectations, history suggests the stock could see a modest uptick, confirming a positive shift in performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average drop of around 4.57% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the eye health segment.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for contact lenses and surgical products.
4Guidance on revenue expectations for the upcoming quarters.
5Any strategic partnerships or collaborations announced.